Background illustration for clinical trials search

Paid Clinical Trials Irving

Discover 1,948 paid clinical trials in Irving, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

for
Graves' Disease
Location: Irving TX, Dallas TX, Fort Worth TX, McKinney TX,
Sponsor: Immunovant Sciences GmbH

Sex: All

Age: 18 - 70+

Code: NCT07018323

Phase 2, Recruiting

PARCA (a Digital Tool) to Improve Justice and Health

for
Behavioral Addiction
Location: Dallas TX, Austin TX
Sponsor: George Mason University

Sex: All

Age: 18+

Code: NCT07199374

Recruiting
New

A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

for
Obesity, Overweight, Diabetes Mellitus, Type 2
Location: Dallas TX, San Antonio TX, Springfield MO, Columbus GA,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18 - 65

Code: NCT07881887

Phase 1, Recruiting
New

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

for
C-Reactive Protein
Location: Dallas TX
Sponsor: Eli Lilly and Company

Sex: All

Age: 18 - 65

Code: NCT07867340

Phase 1, Recruiting
New

Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

for
Obesity, Overweight
Location: Dallas TX, Knoxville TN, Lexington KY, Madison WI,
Sponsor: Amgen

Sex: All

Age: 18 - 70

Code: NCT07908316

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

for
Obesity, Overweight
Location: Dallas TX, Daytona Beach FL
Sponsor: Eli Lilly and Company

Sex: Female

Age: 18 - 60

Code: NCT07808060

Phase 1, Recruiting

A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

for
Obesity, Overweight
Location: Dallas TX, Daytona Beach FL
Sponsor: Eli Lilly and Company

Sex: All

Age: 18 - 65

Code: NCT07808073

Phase 1, Recruiting

A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395

for
Healthy Adult Participants
Location: Dallas TX
Sponsor: BeOne Medicines

Sex: All

Age: 18 - 65

Code: NCT07820891

Phase 1, Recruiting

A Study of LY4355756 in Healthy Participants

for
Healthy
Location: Dallas TX
Sponsor: Eli Lilly and Company

Sex: All

Age: 18 - 65

Code: NCT07765498

Phase 1, Recruiting

A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants

for
Healthy Adult Participants
Location: Dallas TX, Madison WI, Daytona Beach FL
Sponsor: Astria Therapeutics, Inc.

Sex: All

Age: 18 - 55

Code: NCT07635095

Phase 1, Recruiting

A Study of LY4515100 in Healthy Participants

for
Healthy
Location: Dallas TX, Madison WI
Sponsor: Eli Lilly and Company

Sex: All

Age: 18 - 65

Code: NCT07339722

Phase 1, Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

for
Breast Cancer, Locally Advanced Breast Cancer,
Location: Dallas TX, Denton TX, Houston TX, San Antonio TX,
Sponsor: Olema Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07085767

Phase 3, Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

for
Metastatic Colorectal Cancer (CRC)
Location: Dallas TX, Fort Worth TX, Tyler TX, Oklahoma City OK,
Sponsor: Summit Therapeutics

Sex: All

Age: 18+

Code: NCT07228832

Phase 3, Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

for
High Risk Cardiovascular Disease, Hypertension,
Location: Dallas TX, Arlington TX, Euless TX, Duncanville TX,
Sponsor: Alnylam Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07181109

Phase 3, Recruiting

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

for
Congenital Adrenal Hyperplasia,
Location: Dallas TX, Aurora CO, Atlanta GA, Chicago IL,
Sponsor: Crinetics Pharmaceuticals Inc.

Sex: All

Age: 18 - 70+

Code: NCT07144163

Phase 3, Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

for
COVID-19 SARS-CoV-2 Infection
Location: Dallas TX, Lewisville TX, Waco TX, Houston TX,
Sponsor: Pfizer

Sex: All

Age: 12+

Code: NCT06679140

Phase 3, Recruiting

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

for
Peripheral Arterial Disease, Atherosclerosis of Extremities,
Location: Dallas TX, McKinney TX, El Paso TX, Nashville TN,
Sponsor: Population Health Research Institute

Sex: All

Age: 18+

Code: NCT04774159

Phase 3, Recruiting

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

for
Atrial Fibrillation (AF)
Location: Dallas TX, McKinney TX, Lufkin TX, Houston TX,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07430956

Phase 3, Recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

for
Atherosclerosis
Location: Dallas TX, Houston TX, San Antonio TX, St Louis MO,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07448038

Phase 2, Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

for
Heart Failure
Location: Dallas TX, Fort Worth TX, McKinney TX, Longview TX,
Sponsor: Boehringer Ingelheim

Sex: All

Age: 18+

Code: NCT06424288

Phase 3, Recruiting